Abbott Laboratories stock (US0028241000): Q1 2026 growth, guidance raise and diabetes momentum

Abbott Laboratories reported higher Q1 2026 earnings, raised its full-year guidance and highlighted strong growth in its diabetes care business, while the stock remains under pressure after recent declines.

Abbott Laboratories started 2026 with higher earnings and stronger sales, lifted by continued growth in its diabetes care franchise and medical devices, and raised its full-year earnings guidance while maintaining its dividend. The company reported first-quarter 2026 revenue of about $11.2 billion, up roughly 8% year over year, and increased its adjusted EPS outlook for 2026, according to a company update and financial data summarized by Quiver Quant and ad-hoc news on Q1 results Quiver Quant as of 05/17/2026 and ad-hoc-news as of 05/08/2026.

Despite the solid start to the year and a guidance increase, Abbott Laboratories shares have been under pressure in recent months. The stock traded around the mid?$80 range and was down nearly 30% over the past three months, reflecting investor concerns about valuation and near-term growth, based on recent performance data from Appreciate Wealth and other market portals Appreciate Wealth as of 05/17/2026.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare; medical devices, diagnostics, nutrition and branded generics
• Headquarters/country: Abbott Park, Illinois, United States
• Core markets: Global healthcare markets with significant exposure to the United States and Europe
• Key revenue drivers: Diabetes care (including FreeStyle Libre), medical devices, diagnostics, nutrition products and established pharmaceuticals
• Home exchange/listing venue: New York Stock Exchange (ticker: ABT)
• Trading currency: US dollar (USD)

Abbott Laboratories: core business model

Abbott Laboratories is a diversified healthcare company that generates revenue across several major segments, including medical devices, diagnostics, nutrition and established pharmaceutical products. Its business model is built around developing and commercializing technologies and therapies that address chronic diseases and support everyday health. The company’s broad portfolio helps smooth the impact of cyclical swings in any single area.

In medical devices, Abbott Laboratories offers products for cardiovascular care, structural heart interventions, neuromodulation and diabetes management. The diabetes care franchise, which includes the FreeStyle Libre continuous glucose monitoring system, has become a central growth pillar. This business aims to provide people with diabetes with real?time glucose information and is marketed in both the United States and international markets, contributing to recurring sensor and device revenue.

Diagnostics is another core business, covering laboratory instruments and test kits used by hospitals, clinics and reference labs. These systems support clinical decision?making in areas such as infectious disease, blood screening and routine chemistry. Nutrition products, including infant formula and adult nutrition brands, supply a steady demand stream, while the established pharmaceuticals segment focuses mainly on branded generics in emerging markets, providing additional diversification for the company.

Main revenue and product drivers for Abbott Laboratories

Recent results indicate that diabetes care and broader medical devices remain key revenue drivers for Abbott Laboratories. The ad-hoc overview of Q1 2026 results highlighted continued strong momentum in the diabetes business, which contributed to overall revenue growth and margin support, alongside solid performance in medical devices and stable trends in other segments ad-hoc-news as of 05/08/2026.

According to data referenced by Quiver Quant, Abbott Laboratories posted roughly $11.2 billion in revenue in the first quarter of 2026, representing growth of about 7.8% compared with the prior-year period. Higher earnings accompanied this expansion, signalling that the mix of products and cost discipline helped offset pricing pressures and investment spending. Continuous glucose monitoring systems, cardiovascular devices and other high?margin medical products are important factors in sustaining profitability Quiver Quant as of 05/17/2026.

In addition to organic drivers, Abbott Laboratories benefits from recurring revenue streams tied to consumables and subscriptions. Many of its devices require ongoing purchase of sensors, test strips or associated supplies, which supports revenue visibility. At the same time, the company continues to invest in innovation, new product launches and geographic expansion, particularly in areas where rising chronic disease prevalence and growing middle classes support long-term demand for healthcare solutions.

Earnings, guidance and dividend policy in 2026

Q1 2026 marked an important checkpoint for Abbott Laboratories, as the company not only delivered year?on?year growth in revenue and earnings but also raised its full?year 2026 outlook. According to summarised data from MarketBeat, Abbott reported first-quarter earnings per share that were above prior expectations and increased its full?year adjusted EPS guidance range for 2026, signalling management confidence in the demand outlook and cost structure for the rest of the year MarketBeat as of 05/17/2026.

Alongside earnings, the company reaffirmed its commitment to returning cash to shareholders through dividends. Abbott Laboratories maintained its quarterly dividend at $0.63 per share, which implies a dividend yield of around 3% at recent share price levels, based on data from MarketBeat and other market trackers. This continues Abbott’s history as a long?time dividend payer and reflects its balance between funding growth initiatives and providing cash returns to shareholders.

Looking ahead, an upcoming catalyst for investors is the fourth-quarter 2025 earnings release and associated conference call, which Abbott announced earlier in the year. The company plans to report those results before the market opens on January 22, 2026, followed by a webcasted conference call, according to a company notice distributed via PR Newswire and summarized by StockTitan. The event is expected to provide additional context on full?year 2025 performance, capital allocation and the underlying trends that feed into 2026 guidance StockTitan as of 01/05/2026.

Share price performance and market reaction

Despite the positive tone on earnings and guidance, Abbott Laboratories shares have experienced notable volatility in 2026. According to Appreciate Wealth, the stock recently traded at about $84.47, with a 52?week high above this level and a three?month drawdown of around 29%, indicating substantial price pressure over a relatively short period. This pullback has occurred even though the company’s revenue and earnings trends remain broadly supportive, suggesting that sentiment and valuation factors are playing a role Appreciate Wealth as of 05/17/2026.

Market data from Pluang and other financial sites show that Abbott Laboratories shares have traded in the mid?$80 range in recent sessions, with modest daily moves around the Q1 earnings release and subsequent news flow. Some platforms highlight that technical indicators have turned more bearish, with key support levels around $84, while longer?term fundamentals such as revenue over approximately $44 billion in 2025 and a net margin in the low?double?digit range remain intact. These dynamics illustrate the gap that can sometimes open between operating performance and short?term stock price behavior Pluang as of 05/17/2026.

From a broader market perspective, macroeconomic factors and sector rotation trends may also influence the stock. Higher interest rates, shifting investor preferences between defensive and growth sectors, and comparisons with other large healthcare peers all shape how Abbott Laboratories is valued at any given time. For investors watching the US healthcare space, these cross?currents can lead to periods where a stock’s price diverges from its underlying fundamentals, at least in the short term.

Analyst sentiment and institutional activity

Wall Street coverage of Abbott Laboratories remains generally constructive, even as some firms have adjusted their expectations. According to MarketBeat, analysts currently assign the stock a consensus rating in the "Moderate Buy" range, with an average price target around $119. This implies meaningful upside from recent trading levels, although several banks have trimmed their individual targets in response to evolving sector conditions and company?specific factors. These revisions reflect a balancing act between recognizing Abbott’s growth drivers and accounting for execution risks and market volatility MarketBeat as of 05/17/2026.

Institutional investors continue to actively adjust their positions in Abbott Laboratories. For example, MarketBeat reported that iA Global Asset Management reduced its stake in the company by roughly 17.6% in the fourth quarter, selling more than 25,000 shares and ending the period with approximately 118,666 shares. Such portfolio moves can be driven by internal allocation decisions, risk management or relative valuation judgments and do not necessarily reflect a consensus view on the company’s long?term prospects.

At the same time, other large investors may be adding exposure, particularly if they view the share price correction as an opportunity to accumulate stakes in high?quality healthcare franchises. The interplay between buyers and sellers at institutional level can contribute to trading volume spikes and price swings, especially around earnings releases, guidance updates or macroeconomic news that affects the healthcare sector broadly.

Why Abbott Laboratories matters for US investors

For US investors, Abbott Laboratories plays a notable role in the healthcare and medical technology landscape. The company is listed on the New York Stock Exchange under the ticker ABT and is widely held by mutual funds, pension plans and exchange?traded funds. Its scale and diversified business mix mean that developments at Abbott can influence sector indices and healthcare?focused investment products that are popular with US retail and institutional investors.

Abbott’s exposure to long?term themes such as aging populations, rising chronic disease prevalence and continued demand for diagnostics and medical devices gives it a strategic position in the US economy. Products like the FreeStyle Libre system are directly relevant to millions of Americans managing diabetes, while cardiovascular and structural heart devices address critical clinical needs. As healthcare spending in the United States continues to rise over time, companies that provide essential diagnostics and interventions often remain part of the investment discussion.

In addition, Abbott’s status as a dividend payer with a track record of returning cash to shareholders makes it a component of income?oriented portfolios. US investors who focus on dividend growth and defensive characteristics frequently follow the company’s payout decisions and balance sheet metrics closely. Movements in its earnings, guidance and capital allocation policies can therefore have ripple effects across a range of yield?focused strategies.

Conclusion

Abbott Laboratories entered 2026 with higher revenue, improved earnings and a raised full?year guidance range, supported by strong diabetes care momentum and steady contributions from other segments. At the same time, the share price has retreated significantly over the past several months, reflecting a combination of market volatility, valuation debates and institutional portfolio adjustments. For US investors following large healthcare names, the stock illustrates how solid operating trends can coexist with pronounced share price swings.

Future developments in Abbott’s product pipeline, regulatory environment and macroeconomic backdrop will likely influence how the balance between growth, income and risk is perceived. Earnings updates, including the detailed review of full?year 2025 and progress through 2026, should provide additional data points for assessing the company’s trajectory. As with any individual stock, potential investors and current shareholders may wish to consider how Abbott Laboratories fits within a diversified portfolio and aligns with their risk tolerance and investment horizon.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.